CA2492789C - Procede de preparation de microcapsules pharmaceutiques ayant un meilleur masquage du gout et une vitesse de dissolution elevee - Google Patents
Procede de preparation de microcapsules pharmaceutiques ayant un meilleur masquage du gout et une vitesse de dissolution elevee Download PDFInfo
- Publication number
- CA2492789C CA2492789C CA2492789A CA2492789A CA2492789C CA 2492789 C CA2492789 C CA 2492789C CA 2492789 A CA2492789 A CA 2492789A CA 2492789 A CA2492789 A CA 2492789A CA 2492789 C CA2492789 C CA 2492789C
- Authority
- CA
- Canada
- Prior art keywords
- drug
- coating
- microcapsules
- process according
- acrylic polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 34
- 230000008569 process Effects 0.000 title claims abstract description 26
- 238000004090 dissolution Methods 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 47
- 229940079593 drug Drugs 0.000 claims abstract description 46
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 21
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 21
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 21
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims description 34
- 239000011248 coating agent Substances 0.000 claims description 33
- 239000000725 suspension Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011859 microparticle Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005191 phase separation Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 229910010272 inorganic material Inorganic materials 0.000 claims description 4
- 239000011147 inorganic material Substances 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 239000003835 ketolide antibiotic agent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 150000002959 penams Chemical class 0.000 claims description 2
- 150000002961 penems Chemical class 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 235000019640 taste Nutrition 0.000 description 27
- 230000000873 masking effect Effects 0.000 description 19
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 11
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 229960002464 fluoxetine Drugs 0.000 description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- -1 ethanol): 30-94% Chemical compound 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005354 coacervation Methods 0.000 description 3
- 229920001688 coating polymer Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 229920003148 Eudragit® E polymer Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229920003118 cationic copolymer Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention se rapporte à un procédé servant à produire des microcapsules contenant un médicament et comportant une couche d'éthylcellulose et une couche d'un polymère acrylique, ainsi qu'aux microcapsules ainsi produites.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/007961 WO2004009058A1 (fr) | 2002-07-17 | 2002-07-17 | Procede pour la preparation de microcapsules pharmaceutiques avec masquage ameliore du gout et taux de dissolution eleve |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2492789A1 CA2492789A1 (fr) | 2004-01-29 |
| CA2492789C true CA2492789C (fr) | 2012-07-03 |
Family
ID=30470213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2492789A Expired - Fee Related CA2492789C (fr) | 2002-07-17 | 2002-07-17 | Procede de preparation de microcapsules pharmaceutiques ayant un meilleur masquage du gout et une vitesse de dissolution elevee |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050269722A1 (fr) |
| EP (1) | EP1534251A1 (fr) |
| JP (1) | JP4357422B2 (fr) |
| AU (1) | AU2002368090A1 (fr) |
| CA (1) | CA2492789C (fr) |
| WO (1) | WO2004009058A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US20070098746A1 (en) * | 2005-11-02 | 2007-05-03 | Nichols William M | Multi-layered coating technology for taste masking |
| CN102958515A (zh) | 2009-12-02 | 2013-03-06 | 阿普塔利斯制药有限公司 | 非索非那定微胶囊及含有非索非那定微胶囊的组合物 |
| CN103655483A (zh) * | 2012-09-26 | 2014-03-26 | 扬州市星斗药业有限公司 | 一种含有替比培南的颗粒及其制备方法 |
| EP3865124A1 (fr) * | 2012-12-28 | 2021-08-18 | I.P.S. International Products & Services S.r.l. | Matrice polymérique polyvalente pour préparations orales solides à libération modifiée et procédé de préparation associé |
| JP6572244B2 (ja) | 2014-02-25 | 2019-09-04 | オービス バイオサイエンシズ, インク.Orbis Biosciences, Inc. | 味覚マスキング薬製剤 |
| CN103893150B (zh) * | 2014-03-28 | 2016-06-08 | 北京联合大学 | 一种青霉素v钾微囊及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3900811A1 (de) * | 1989-01-13 | 1990-07-19 | Kali Chemie Pharma Gmbh | Neue arzneiform |
| DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
| US6197347B1 (en) * | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
| ES2601855T3 (es) * | 1998-11-25 | 2017-02-16 | Cima Labs Inc. | Comprimido de liberación rápida con núcleo recubierto que contiene el fármaco y capa circundante de enmascaramiento del sabor |
| FR2795962B1 (fr) * | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| US6451345B1 (en) * | 2000-01-20 | 2002-09-17 | Eurand Pharmaceuticals Ltd. | Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration |
-
2002
- 2002-07-17 WO PCT/EP2002/007961 patent/WO2004009058A1/fr not_active Ceased
- 2002-07-17 CA CA2492789A patent/CA2492789C/fr not_active Expired - Fee Related
- 2002-07-17 AU AU2002368090A patent/AU2002368090A1/en not_active Abandoned
- 2002-07-17 JP JP2004522144A patent/JP4357422B2/ja not_active Expired - Fee Related
- 2002-07-17 US US10/521,598 patent/US20050269722A1/en not_active Abandoned
- 2002-07-17 EP EP02807606A patent/EP1534251A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1534251A1 (fr) | 2005-06-01 |
| CA2492789A1 (fr) | 2004-01-29 |
| AU2002368090A1 (en) | 2004-02-09 |
| US20050269722A1 (en) | 2005-12-08 |
| JP4357422B2 (ja) | 2009-11-04 |
| WO2004009058A1 (fr) | 2004-01-29 |
| JP2005537270A (ja) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101571198B1 (ko) | 중성 비닐 중합체 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물 | |
| JP4615124B2 (ja) | 制御された作用物質放出性を有する被覆された医薬品形 | |
| Hari et al. | Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin | |
| CA2492789C (fr) | Procede de preparation de microcapsules pharmaceutiques ayant un meilleur masquage du gout et une vitesse de dissolution elevee | |
| JP4732696B2 (ja) | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 | |
| JP6173912B2 (ja) | マイクロカプセル化プロセスおよび製品 | |
| US20030180352A1 (en) | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | |
| JP4555980B2 (ja) | 疎水性重合体でコートされた芯を有している吸湿性マイクロカプセル | |
| SK1032000A3 (en) | Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production | |
| HU215128B (hu) | Eljárás pH-függő áteresztőképességű határréteggel ellátott, nyújtott hatóanyag-leadású gyógyszerkészítmények előállítására | |
| SK792001A3 (en) | Coating and excipient agent for oral or dermal dosage forms | |
| HRP20020119A2 (en) | Taste masked pharmaceutical liquid formulations | |
| CZ87998A3 (cs) | Směs obsahující acidolabilní omeprazol a způsob její přípravy | |
| JP4234427B2 (ja) | 活性成分をベースとする微小顆粒およびその製造方法 | |
| MXPA05008193A (es) | Particulas con revestimiento que oculta el sabor, proceso para la preparacion de las mismas y tabletas orodispersables que contienen dichas particulas revestidas. | |
| CN1713896B (zh) | 球形体、其制备方法以及药物组合物 | |
| CN1956707B (zh) | 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型 | |
| EP1781275B2 (fr) | Composition pharmaceutique de tolterodine a liberation prolongee | |
| AU2004289222B2 (en) | Compositions of quaternary ammonium containing bioavailability enhancers | |
| WO2008005287A1 (fr) | Compositions pharmaceutiques comprenant une combinaison de pipéridinoalcanol et d'un décongestionnant | |
| Sarkar et al. | Study of ethyl cellulose based sustained release microspheres of naproxen sodium | |
| Boles et al. | Microencapsulation studies on aminophylline involving spherical crystallization, spheronization and drug loading on to non-pareil seeds | |
| JPH11209306A (ja) | 高薬物含有率徐放製剤の製法 | |
| WO2001035930A1 (fr) | Compositions orales a gout masque | |
| Donbrow | Medicine and Pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |